<DOC>
	<DOCNO>NCT01869400</DOCNO>
	<brief_summary>Clinical trial , due inclusion exclusion criterion , accomplish define patient group , representative whole patient population . Especially elderly patient patient co-morbidities underrepresented clinical trial . This non-interventional study examine efficiency toxicity Yondelis® + PLD combination therapy general patient population evaluate data collect clinical trial assign general patient population .</brief_summary>
	<brief_title>An Observational Study YONDELIS®+PLD Treatment Patients With Platinum-sensitive Relapse Ovarian Cancer</brief_title>
	<detailed_description>Yondelis® ( trabectedin ) approve ( combination PLD ) European community December 2009 treatment platinum-sensitive ovarian cancer relapse . Based outcome study OVA-301 , non-interventional study investigate role platinum-free treatment regimen patient progressive ovarian cancer relapse &gt; 6 month complete previous platinum-based chemotherapy . In particular , study aim collect `` real-life '' data regard response influence mention therapy `` tumor related event '' , objectify value palliative care .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Women age &gt; 18 , upper limit Patients relapse platinumsensitive ovarian cancer Before inclusion NIS write informed consent must give According summary product characteristic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>